| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Discovery of a new lead molecule to develop a novel class of human factor XIIa inhibitors
|
Dumas, Anthony
|
|
|
57 |
8 |
p. 1308-1314
|
artikel
|
| 2 |
Factor XIa inhibition as a therapeutic strategy for atherothrombosis
|
Bailey, Eric
|
|
|
57 |
8 |
p. 1297-1307
|
artikel
|
| 3 |
Factor XI: structure, function and therapeutic inhibition
|
Ali, Ahmed E.
|
|
|
57 |
8 |
p. 1315-1328
|
artikel
|
| 4 |
Heparin-like effect of a dual antiplatelet and anticoagulant (APAC) agent on red blood cell deformability and aggregation in an experimental model
|
Matrai, Adam Attila
|
|
|
57 |
8 |
p. 1329-1338
|
artikel
|
| 5 |
Novel antithrombotic approaches in cardiovascular disease – what is on the horizon?
|
Barnes, Geoffrey D.
|
|
|
57 |
8 |
p. 1281-1282
|
artikel
|
| 6 |
RNAi targeting LMAN1-MCFD2 complex promotes anticoagulation in mice
|
Ma, Siqian
|
|
|
57 |
8 |
p. 1349-1362
|
artikel
|
| 7 |
The factor XI/XIa antibody abelacimab combined with enoxaparin inhibits filter clotting in hemodialysis circuits ex vivo
|
Grafeneder, Juergen
|
|
|
57 |
8 |
p. 1339-1348
|
artikel
|
| 8 |
The foundation for investigating factor XI as a target for inhibition in human cardiovascular disease
|
Ali, Ahmed E.
|
|
|
57 |
8 |
p. 1283-1296
|
artikel
|
| 9 |
The potential role of factor XI inhibitors in managing long COVID
|
Kow, Chia Siang
|
|
|
57 |
8 |
p. 1363-1364
|
artikel
|
Tijdschrift beschrijving